<DOC>
	<DOCNO>NCT00943709</DOCNO>
	<brief_summary>RATIONALE : Controlling blood sugar level may effective prevent infection patient receive chemotherapy acute myeloid leukemia acute lymphoblastic leukemia . PURPOSE : This randomized phase I trial study well control blood sugar level work prevent infection patient acute myeloid leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Intensive Glycemic Control Infectious Morbidity In Patients With Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether intensive glycemic control eight week time period decrease incidence infection initiation chemotherapy treatment patient acute myeloid leukemia acute lymphoblastic leukemia . Secondary - To compare number episodes infection . - To compare duration neutropenia . - To compare number day bacteremia/fungemia . - To compare number day fever . - To compare duration nutrition . - To compare duration mucositis . - To compare duration hospital stay . - To compare duration antibiotic use . - To compare incidence thromboembolic event . - To compare body weight change . - To compare median survival . - To compare remission rate induction salvage chemotherapy . - To conduct comparative analysis intervention standard care group mean daily capillary blood glucose monitoring . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I ( intensive glycemic control ) : Patients goal blood glucose 80-140 mg/dL receive Robert Wood Johnson University Hospital IV insulin infusion protocol maintain blood glucose target range . Beginning 24 hour maintenance oral enteral feeding patient receive intensive regimen insulin glargine insulin glulisine ( Apidra™ ) subcutaneously 4 week need . Patients may also receive insulin total parenteral nutrition ( TPN ) mixture . - Arm II ( standard care control ) : Patients goal blood glucose &lt; 250 mg/dL start subcutaneous insulin slide scale discretion treat physician blood glucose monitoring adjustment accord insulin slide scale . Insulin may also add TPN need investigator 's discretion . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia acute lymphoid leukemia Newly diagnose relapsed disease Undergoing induction salvage chemotherapy treatment Must demonstrate 2 random blood sugar ≥ 140 mg/dL total parenteral nutrition ( TPN ) OR 2 preprandial sugar ≥ 140 mg/dL patient TPN PATIENT CHARACTERISTICS : ECOG performance status 03 Not pregnant nursing Negative pregnancy test Prior diagnosis diabetes mellitus allow No known history allergy insulin No document active infection PRIOR CONCURRENT THERAPY : Concurrent corticosteroid allow No concurrent oral hypoglycemic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>hyperglycemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>